MRI contrast developer Epix Pharmaceuticals has formed a technology advisory board to help the company with its in silico modeling drug discovery platform, the Lexington, MA-based company said.
Board members include the following:
- Charles Brooks, Ph.D., a Warner-Lambert/Parke-Davis professor of chemistry and a professor of biophysics in the Department of Chemistry at the University of Michigan
- Johan Aqvist, Ph.D., a professor of theoretical chemistry in the Department of Cell and Molecular Biology at Uppsala University, Sweden
- Gabriele Cruciani, Ph.D., a professor of organic chemistry and cheminformatics in the Laboratory for Chemometrics and Cheminformatics at the University of Perugia, Italy
Related Reading
Epix's Q2 results show boosted revenues, August 7, 2008
Epix secures equity financing, August 5, 2008
Epix CEO resigns, July 28, 2008
Epix wins South Korean approval of Vasovist, July 10, 2008
Epix resubmits Vasovist NDA, July 1, 2008
Copyright © 2008 AuntMinnie.com
